Mga Batayang Estadistika
| LEI | 391200Z8UWPJSNBNCA11 |
| CIK | 1840904 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Atai Life Sciences N.V.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40493 ATAI Life Sciences N. |
|
| August 14, 2025 |
Exhibit 10.17 BECKLEY PSYTECH LIMITED SENIOR PROMISSORY NOTE August 13, 2025 USD $10,000,000.00 Effective as of the date set forth above (the “Effective Date”), BECKLEY PSYTECH LIMITED, a private company limited by shares incorporated under the laws of England and Wales, with company number 11496099, whose registered office address is at Beckley Park, Beckley, Oxford, England OX3 9SY (the “Company |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2025 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation o |
|
| August 14, 2025 |
Articles of Association of ATAI Life Sciences N.V. (translated into English), currently in effect Exhibit 3.1 1 DOORLOPENDE TEKST van de statuten van ATAI Life Sciences N.V., statutair gevestigd te Amsterdam, na partiële statutenwijziging bij akte op 25 juni 2025 verleden voor Paul Cornelis Simon van der Bijl, notaris te Amsterdam. Handelsregister nummer 80299776. STATUTEN definities en interpretatie Artikel 1 1.1 In deze statuten gelden de volgende definities: Algemene Vergadering De algemene |
|
| August 14, 2025 |
Compensation Policy of ATAI Life Sciences N.V. Exhibit 10.3 1 COMPENSATION POLICY ATAI LIFE SCIENCES N.V. INTRODUCTION Article 1 This document sets out the Company's policy concerning the compensation of the Directors. DEFINITIONS AND INTERPRETATION Article 2 2.1 In this policy the following definitions shall apply: Article An article of this policy. Board The Company's board of directors. Change of Control Benefit Any compensation or other be |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2025 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation o |
|
| August 14, 2025 |
Exhibit 99.1 atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates Planned strategic combination with Beckley Psytech expected to solidify position as global leader in transformative, psychedelic-based mental health therapies with a short time in-clinic • Reported positive topline data from the core, blinded stage of the Phase 2b clinical trial of BPL-003 (i |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☒ Soliciting Material under § 240. |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☒ Soliciting Material under § 240. |
|
| July 1, 2025 |
Exhibit 99.2 atai Life Sciences Announces $50 Million Private Placement Financing Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1 NEW YORK and AMSTERDAM – 1 JULY 2025 - atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company |
|
| July 1, 2025 |
Exhibit 99.1 atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression ● Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single dose ● Both 8 mg and 12 mg single doses of BPL-003 showed statistically significant an |
|
| July 1, 2025 |
Exhibit 10.5 REGISTRATION RIGHTS AGREEMENT by and among ATAI LIFE SCIENCES N.V., AND THE OTHER HOLDERS FROM TIME TO TIME PARTIES HERETO Dated as of July 1, 2025 TABLE OF CONTENTS PAGE ARTICLE I DEFINITIONS 2 SECTION 1.01 Definitions 2 ARTICLE II REGISTRATION RIGHTS 4 SECTION 2.01 Resale Shelf Registration 4 SECTION 2.02 Registration Procedures 5 SECTION 2.03 Registration Expenses 8 SECTION 2.04 In |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2025 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or o |
|
| July 1, 2025 |
Exhibit 10.2 THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS THEREUNDER. THE SECURITIES PURCHASED HEREUNDER MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND OTHE |
|
| July 1, 2025 |
Exhibit 10.2 THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS THEREUNDER. THE SECURITIES PURCHASED HEREUNDER MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND OTHE |
|
| July 1, 2025 |
Exhibit 10.4 PURSUANT TO THE TERMS OF THIS WARRANT, ALL OR A PORTION OF THIS WARRANT MAY HAVE BEEN EXERCISED OR CANCELED, AND THEREFORE THE ACTUAL NUMBER OF WARRANT SHARES REPRESENTED BY THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF. ANY TRANSFEREE OF THIS WARRANT SHOULD CONTACT ATAI LIFE SCIENCES N.V. IN ADVANCE OF ACQUIRING THIS WARRANT TO BE APPRISED OF THE ACTUAL NUMBE |
|
| July 1, 2025 |
Exhibit 10.5 REGISTRATION RIGHTS AGREEMENT by and among ATAI LIFE SCIENCES N.V., AND THE OTHER HOLDERS FROM TIME TO TIME PARTIES HERETO Dated as of July 1, 2025 TABLE OF CONTENTS PAGE ARTICLE I DEFINITIONS 2 SECTION 1.01 Definitions 2 ARTICLE II REGISTRATION RIGHTS 4 SECTION 2.01 Resale Shelf Registration 4 SECTION 2.02 Registration Procedures 5 SECTION 2.03 Registration Expenses 8 SECTION 2.04 In |
|
| July 1, 2025 |
FORM OF PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT ATAI LIFE SCIENCES N.V. Exhibit 10.4 PURSUANT TO THE TERMS OF THIS WARRANT, ALL OR A PORTION OF THIS WARRANT MAY HAVE BEEN EXERCISED OR CANCELED, AND THEREFORE THE ACTUAL NUMBER OF WARRANT SHARES REPRESENTED BY THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF. ANY TRANSFEREE OF THIS WARRANT SHOULD CONTACT ATAI LIFE SCIENCES N.V. IN ADVANCE OF ACQUIRING THIS WARRANT TO BE APPRISED OF THE ACTUAL NUMBE |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2025 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or o |
|
| July 1, 2025 |
Exhibit 99.1 atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression ● Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single dose ● Both 8 mg and 12 mg single doses of BPL-003 showed statistically significant an |
|
| July 1, 2025 |
Exhibit 10.3 THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS THEREUNDER. THE SECURITIES PURCHASED HEREUNDER MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND OTHE |
|
| July 1, 2025 |
Form of Subscription Agreement Exhibit 10.1 THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS THEREUNDER. THE SECURITIES PURCHASED HEREUNDER MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND OTHE |
|
| July 1, 2025 |
FORM OF SUBSCRIPTION AGREEMENT Exhibit 10.1 THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS THEREUNDER. THE SECURITIES PURCHASED HEREUNDER MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND OTHE |
|
| July 1, 2025 |
Exhibit 99.2 atai Life Sciences Announces $50 Million Private Placement Financing Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1 NEW YORK and AMSTERDAM – 1 JULY 2025 - atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company |
|
| July 1, 2025 |
Exhibit 99.3 July 1, 2025 atai Life Sciences and Beckley Psytech Announce Positive Topline Data from Phase 2b Study of BPL-003 for Treatment-Resistant Depression All references in this presentation to “we”, “us”, “our”, “atai”, or the “Company” refer to ATAI Life Sciences N.V. and its consolidated subsidiaries, unless the context otherwise requires. This presentation contains forward-looking state |
|
| July 1, 2025 |
Exhibit 99.3 July 1, 2025 atai Life Sciences and Beckley Psytech Announce Positive Topline Data from Phase 2b Study of BPL-003 for Treatment-Resistant Depression All references in this presentation to “we”, “us”, “our”, “atai”, or the “Company” refer to ATAI Life Sciences N.V. and its consolidated subsidiaries, unless the context otherwise requires. This presentation contains forward-looking state |
|
| July 1, 2025 |
Exhibit 10.3 THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS THEREUNDER. THE SECURITIES PURCHASED HEREUNDER MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT AND OTHE |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☒ Soliciting Material under § 240. |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☒ Soliciting Material under § 240. |
|
| June 2, 2025 |
FORM OF PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT ATAI LIFE SCIENCES N.V. Exhibit 10.7 PURSUANT TO THE TERMS OF THIS WARRANT, ALL OR A PORTION OF THIS WARRANT MAY HAVE BEEN EXERCISED OR CANCELED, AND THEREFORE THE ACTUAL NUMBER OF WARRANT SHARES REPRESENTED BY THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF. ANY TRANSFEREE OF THIS WARRANT SHOULD CONTACT ATAI LIFE SCIENCES N.V. IN ADVANCE OF ACQUIRING THIS WARRANT TO BE APPRISED OF THE ACTUAL NUMBE |
|
| June 2, 2025 |
false000184090400-000000000018409042025-06-022025-06-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 2, 2025 |
Exhibit 10.1 FORM OF VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), dated as of June 2, 2025, is by and among Beckley Psytech Limited, a company incorporated in England and Wales with company number 11496099, whose registered office is at Beckley Park, Beckley, Oxford, England OX3 9SY (“Beckley”), Atai Life Sciences N.V., a company incorporated in the Netherlands with company number 80 |
|
| June 2, 2025 |
Exhibit 10.4 Lock-Up Agreement June 2, 2025 ATAI Life Sciences N.V. Wallstraße 16 10179 Berlin Germany Ladies and Gentlemen: The undersigned understands that ATAI Life Sciences N.V. (the “Company”) will enter into that certain Share Purchase Agreement dated on or about the date hereof (the “Share Purchase Agreement”) between, amongst others, certain shareholders of Beckley Psytech Limited and the |
|
| June 2, 2025 |
Exhibit 2.1 EXECUTION VERSION June 2, 2025 THE SELLERS details of whom are set out in Schedule 1 and THE OPTIONHOLDERS details of whom are set out in Schedule 10 and ATAI LIFE SCIENCES N.V. (as Buyer) and BECKLEY PSYTECH LIMITED (as the Company) SHARE PURCHASE AGREEMENT related to BECKLEY PSYTECH LIMITED 99 Bishopsgate London EC2M 3XF United Kingdom Tel: +44.20.7710.1000 www.lw.com TABLE OF CONTEN |
|
| June 2, 2025 |
Exhibit 10.3 SHAREHOLDER RIGHTS AGREEMENT This SHAREHOLDER RIGHTS AGREEMENT, dated as of June 2, 2025 (as amended or restated from time to time, this “Agreement”), is made by and between ATAI Life Sciences N.V., a company incorporated in the Netherlands with company number 80299776, whose registered office is at Wallstraße 16, 10179 Berlin, Germany (the “Company”) and Apeiron Investment Group Ltd |
|
| June 2, 2025 |
Exhibit 10.1 FORM OF VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), dated as of June 2, 2025, is by and among Beckley Psytech Limited, a company incorporated in England and Wales with company number 11496099, whose registered office is at Beckley Park, Beckley, Oxford, England OX3 9SY (“Beckley”), Atai Life Sciences N.V., a company incorporated in the Netherlands with company number 80 |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☒ Soliciting Material under § 240. |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☐ Definitive Additional Materials ☒ Soliciting Material under § 240. |
|
| June 2, 2025 |
Exhibit 10.6 Execution Version THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS THEREUNDER. THE SECURITIES PURCHASED HEREUNDER MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECUR |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 2, 2025 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or o |
|
| June 2, 2025 |
Exhibit 10.2 VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), dated as of June 2, 2025, is by and among Beckley Psytech Limited, a company incorporated in England and Wales with company number 11496099, whose registered office is at Beckley Park, Beckley, Oxford, England OX3 9SY (“Beckley”), Atai Life Sciences N.V., a company incorporated in the Netherlands with company number 80299776, |
|
| June 2, 2025 |
Exhibit 10.8 REGISTRATION RIGHTS AGREEMENT by and among ATAI LIFE SCIENCES N.V., APEIRON INVESTMENT GROUP LTD, FERRING VENTURES S.A., ADAGE CAPITAL PARTNERS LP AND THE OTHER HOLDERS FROM TIME TO TIME PARTIES HERETO Dated as of June 2, 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 SECTION 1.01 Definitions 1 ARTICLE II REGISTRATION RIGHTS 4 SECTION 2.01 Resale Shelf Registration 4 SECTION 2.02 |
|
| June 2, 2025 |
Exhibit 10.8 REGISTRATION RIGHTS AGREEMENT by and among ATAI LIFE SCIENCES N.V., APEIRON INVESTMENT GROUP LTD, FERRING VENTURES S.A., ADAGE CAPITAL PARTNERS LP AND THE OTHER HOLDERS FROM TIME TO TIME PARTIES HERETO Dated as of June 2, 2025 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 SECTION 1.01 Definitions 1 ARTICLE II REGISTRATION RIGHTS 4 SECTION 2.01 Resale Shelf Registration 4 SECTION 2.02 |
|
| June 2, 2025 |
Exhibit 2.1 EXECUTION VERSION June 2, 2025 THE SELLERS details of whom are set out in Schedule 1 and THE OPTIONHOLDERS details of whom are set out in Schedule 10 and ATAI LIFE SCIENCES N.V. (as Buyer) and BECKLEY PSYTECH LIMITED (as the Company) SHARE PURCHASE AGREEMENT related to BECKLEY PSYTECH LIMITED 99 Bishopsgate London EC2M 3XF United Kingdom Tel: +44.20.7710.1000 www.lw.com TABLE OF CONTEN |
|
| June 2, 2025 |
Exhibit 10.6 Execution Version THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS THEREUNDER. THE SECURITIES PURCHASED HEREUNDER MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECUR |
|
| June 2, 2025 |
Exhibit 10.3 SHAREHOLDER RIGHTS AGREEMENT This SHAREHOLDER RIGHTS AGREEMENT, dated as of June 2, 2025 (as amended or restated from time to time, this “Agreement”), is made by and between ATAI Life Sciences N.V., a company incorporated in the Netherlands with company number 80299776, whose registered office is at Wallstraße 16, 10179 Berlin, Germany (the “Company”) and Apeiron Investment Group Ltd |
|
| June 2, 2025 |
Lock-Up Agreement, dated as of June 2, 2025 between the Company and Aperion Investment Group Ltd. Exhibit 10.4 Lock-Up Agreement June 2, 2025 ATAI Life Sciences N.V. Wallstraße 16 10179 Berlin Germany Ladies and Gentlemen: The undersigned understands that ATAI Life Sciences N.V. (the “Company”) will enter into that certain Share Purchase Agreement dated on or about the date hereof (the “Share Purchase Agreement”) between, amongst others, certain shareholders of Beckley Psytech Limited and the |
|
| June 2, 2025 |
Exhibit 10.5 Execution Version THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS THEREUNDER. THE SECURITIES PURCHASED HEREUNDER MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECUR |
|
| June 2, 2025 |
Exhibit 99.1 atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies ● Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinic ● Combined company will |
|
| June 2, 2025 |
Exhibit 10.7 PURSUANT TO THE TERMS OF THIS WARRANT, ALL OR A PORTION OF THIS WARRANT MAY HAVE BEEN EXERCISED OR CANCELED, AND THEREFORE THE ACTUAL NUMBER OF WARRANT SHARES REPRESENTED BY THIS WARRANT MAY BE LESS THAN THE AMOUNTS SET FORTH ON THE FACE HEREOF. ANY TRANSFEREE OF THIS WARRANT SHOULD CONTACT ATAI LIFE SCIENCES N.V. IN ADVANCE OF ACQUIRING THIS WARRANT TO BE APPRISED OF THE ACTUAL NUMBE |
|
| June 2, 2025 |
Exhibit 10.2 VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”), dated as of June 2, 2025, is by and among Beckley Psytech Limited, a company incorporated in England and Wales with company number 11496099, whose registered office is at Beckley Park, Beckley, Oxford, England OX3 9SY (“Beckley”), Atai Life Sciences N.V., a company incorporated in the Netherlands with company number 80299776, |
|
| June 2, 2025 |
Exhibit 99.1 atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies ● Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinic ● Combined company will |
|
| June 2, 2025 |
Exhibit 10.5 Execution Version THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS THEREUNDER. THE SECURITIES PURCHASED HEREUNDER MAY NOT BE TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE SECUR |
|
| May 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2025 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or o |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2025 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or o |
|
| May 14, 2025 |
Exhibit 99.1 atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates With clinical momentum across its pipeline, atai strengthens its position as a leader in potentially transformative psychedelic mental health treatments • Anticipate topline data midyear from the Phase 2b clinical trial of BPL-003 in patients with treatment-resistant depression (TRD) - the lar |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40493 ATAI Life Sciences N. |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 2, 2025 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or or |
|
| April 30, 2025 |
Consulting Agreement between Sahil Kirpekar and atai Life Sciences AG, dated April 3, 2025 Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is made and entered into as of April 3, 2025 (the “Effective Date”) by and between Sahil Kirpekar, with an address at [●] (“Consultant”), and atai Life Sciences AG, a German Public Limited Company having a principal place of business at Wallstraße 16, 10179, Berlin, Germany (“atai”). Both atai and Company may each herei |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 24, 2025 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or |
|
| April 30, 2025 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Separation Agreement and Release This Separation Agreement and Release (“Agreement”) is made by and between Sahil Kirpekar (“Executive”) and ATAI Life |
|
| April 21, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 11, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 20, 2025 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or |
|
| March 17, 2025 |
Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction of Incorporation atai Holdco, Inc. Delaware atai Life Sciences US, Inc. Delaware atai Life Sciences AG Germany atai Life Sciences UK Ltd England and Wales atai Therapeutics, Inc. (f.k.a. Viridia Life Sciences, Inc.) Delaware atai Therapeutics Holdings, Inc. Delaware EmpathBio, Inc. Delaware GABA Therapeutics, Inc. Delaware IntelGenx Cor |
|
| March 17, 2025 |
Exhibit 99.1 atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights - Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26 - Initiated a Phase 2 clinical trial of EMP-01 (oral R-MDMA) for patients with social anxiety; topline data a |
|
| March 17, 2025 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED ATAI Life Sciences N.V. (the “Company,” “we,” “us” and “our”) has the following class of securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common shares, par val |
|
| March 17, 2025 |
Insider Trading Compliance Policy Exhibit 19.1 ATAI LIFE SCIENCES N.V. INSIDER TRADING COMPLIANCE POLICY Federal and state laws prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from providing this information to others who may trade. Violating such laws |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 17, 2025 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or |
|
| March 17, 2025 |
Page 1 von 18 Exhibit 10.4 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), is made and entered into as of the 10th of May 2023 (the “Effective Date”), by and between atai Life Sciences US, Inc. a Delaware corporation (the “Company”) and Anne Johnson (the “Executive”). The Company and the Executive may each be referred to in this Agreemen |
|
| March 17, 2025 |
Exhibit 10.3 SECONDMENT LETTER ENTSENDEBESTÄTIGUNG of / der atai Life Sciences US Inc. c/o Industrious NYC 250 West 34th St New York, NY 10119 (hereinafter “Home Company”) (nachfolgend “Heimatgesellschaft”) to / an Srinivas Rao 1477 Paseo de las Flores Encinitas, CA 92024 (hereinafter "You") (nachfolgend “Sie”) October 17, 2024 / New York We are pleased to confirm your long-term international seco |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . |
|
| March 17, 2025 |
Exhibit 10.28 CONSENT AND FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This CONSENT AND FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Consent and Amendment”) is dated as of January 6, 2025 and is entered into by and among ATAI LIFE SCIENCES N.V., a public limited liability company (naamloze vennootschap) incorporated under the laws of the Netherlands, having its corporate seat (statuta |
|
| February 13, 2025 |
atai Life Sciences Announces Pricing of Public Offering of Common Shares Exhibit 99.1 atai Life Sciences Announces Pricing of Public Offering of Common Shares NEW YORK and BERLIN, February 12, 2025 – atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced the pricing of a registered underwritten offering of 26,190,477 common shares, at a price o |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 12, 2025 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation |
|
| February 13, 2025 |
26,190,477 Shares ATAI LIFE SCIENCES N.V. COMMON SHARES, €0.10 PAR VALUE UNDERWRITING AGREEMENT Exhibit 1.1 26,190,477 Shares ATAI LIFE SCIENCES N.V. COMMON SHARES, €0.10 PAR VALUE UNDERWRITING AGREEMENT February 12, 2025 February 12, 2025 Berenberg Capital Markets LLC As the Underwriter listed in Schedule I hereto c/o Berenberg Capital Markets LLC 1251 Avenue of the Americas, 53rd Floor New York, NY 10020 Ladies and Gentlemen: ATAI Life Sciences N.V., a Dutch public company with limited lia |
|
| February 13, 2025 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-265970 PROSPECTUS SUPPLEMENT (to Prospectus dated July 11, 2022) 26,190,477 Common Shares We are offering 26,190,477 common shares, nominal value €0.10 per share, at a purchase price of $2.10 per share. Our common shares are listed on the Nasdaq Global Market under the symbol “ATAI.” On February 12, 2025, the last reported s |
|
| February 12, 2025 |
Subject to Completion Preliminary Prospectus Supplement dated February 12, 2025 TABLE OF CONTENTS The information in this prospectus supplement is not complete and may be changed. |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 19, 2025 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation |
|
| January 10, 2025 |
Exhibit 99.1 atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health - Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer - Kevin Craig, M.D. promoted to Chief Medical Officer - Glenn Short, Ph.D. promoted to Chief Scientific Officer - Gerd Kochendoerfer Ph.D. joins as Chief Operating Officer NEW YORK a |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2025 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation o |
|
| January 10, 2025 |
Exhibit 10.2 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), is made and entered into as of this 11th of November 2024, by and between ATAI Life Sciences US, Inc. a Delaware corporation (the “Company”) and Gerd Kochendoerfer (the “Executive”). The Company and the Executive may each be referred to in this Agreement individually, as a “Party” and collectively, |
|
| January 10, 2025 |
Exhibit 10.1 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the dates next to the signatures below, by and between ATAI Life Sciences US, Inc. a Delaware corporation (the “Company”) and Srinivas Rao (the “Executive”). The Company and the Executive may each be referred to in this Agreement indi |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A Amendment No. |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2024 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40493 ATAI Life Sciences N. |
|
| November 13, 2024 |
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates Exhibit 99.1 atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to initiate a Phase 2 study in treatment-resistant depression patients around YE’24 - Remain on track to initiate a Phase 2 study of EMP-01 (oral R-MDM |
|
| November 13, 2024 |
Exhibit 99.1 Healing mental health disorders so that everyone everywhere can live a more fulfilled life. Company Overview Company Overview – November 2024 All references in this presentation to “we”, “us”, “our”, “atai”, or the “Company” refer to ATAI Life Sciences N.V. and its consolidated subsidiaries, unless the context otherwise requires. This presentation contains forward-looking statements w |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 2, 2024 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation o |
|
| September 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* COMPASS Pathways plc (Name of Issuer) Ordinary Shares** (Title of Class of Securities) 20451W101** (CUSIP Number) Ryan Barrett ATAI Life Sciences AG Wallstraße 16, 10179 Berlin, Germany +49 (0) 89 2153 9035 (Name, Address and Telephone Number of Person A |
|
| August 14, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT This THIRD Amendment to Loan and Security Agreement (this “Amendment”) is dated as of August 14, 2024 a |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 14, 2024 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation o |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40493 ATAI Life Sciences N. |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2024 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation o |
|
| August 13, 2024 |
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates Exhibit 99.1 atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE’24 - Announced clinical development plans for EMP-01 (oral R-MDMA); expect to initiate a Phase 2 study of EMP-01 in social anxiety disord |
|
| June 5, 2024 |
Exhibit 99.1 Healingmental health disorders so that everyone everywhere can live a more fulfilled life. Company Overview Company Overview – June 2024 All references in this presentation to “we”, “us”, “our”, “atai”, or the “Company” refer to ATAI Life Sciences N.V. and its consolidated subsidiaries, unless the context otherwise requires. This presentation contains forward-looking statements within |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 5, 2024 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or o |
|
| May 23, 2024 |
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors Exhibit 99.1 atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) – atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 17, 2024 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or o |
|
| May 15, 2024 |
Exhibit 10.5 [***] Certain information in this document has been omitted from this exhibit because (i) the Company customarily and actually treats such information as private or confidential and (ii) the omitted information is not material.] EXECUTION COPY FOURTH AMENDMENT TO SERIES A PREFERRED STOCK PURCHASE AGREEMENT THIS FOURTH AMENDMENT TO SERIES A PREFERRED STOCK PURCHASE AGREEMENT (this “Ame |
|
| May 15, 2024 |
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates Exhibit 99.1 atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates • First participant dosed in Phase 1b trial of VLS-01 with data expected in 2H’24; Phase 2 study in TRD patients anticipated to initiate around YE’24 • Beckley Psytech’s Phase 2a study of BPL-003 in TRD patients showed rapid and durable antidepressant effects; Phase 2b topline data expected in 2H’24 |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40493 ATAI Life Sciences N. |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2024 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or o |
|
| May 15, 2024 |
Separation Agreement, by and between the Company and Florian Brand, dated May 14, 2024 Exhibit 10.1 SEPARATION AGREEMENT (hereinafter referred to as “Separation Agreement”) between ATAI LIFE SCIENCES N.V. Wallstraße 16, 10179 Berlin, Germany ("Company”) and Florian Brand [ ●] (“Executive”) Jointly the “Parties” the following is agreed: Executive is currently Chief Executive Officer of the Company (the “CEO”) and of the companies affiliated with the Company (hereinafter only "Affilia |
|
| May 3, 2024 |
IGXT / IntelGenx Technologies Corp. / ATAI Life Sciences B.V. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* IntelGenx Technologies Corp. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 45822R101 (CUSIP Number) Ryan Barrett ATAI Life Sciences AG Wallstraße 16, 10179 Berlin, Germany +49 (0) 89 2153 9035 (Name, |
|
| April 22, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 12, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2024 ATAI Life Sciences N.V. (Exact name of registrant as specified in its charter) The Netherlands (State or other jurisdiction of incorporation or organization) 001-40493 |
|
| March 28, 2024 |
Exhibit 99.1 atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights • Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato® • Initial BPL-003 (intranasal 5-MeO-DMT) Phase 2a open-label results demons |
|
| March 28, 2024 |
Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 ATAI LIFE SCIENCES N.V. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION ATAI Life Sciences N.V. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject to Po |
|
| March 28, 2024 |
Exhibit 21.1 Subsidiaries of the Registrant Name Jurisdiction of Incorporation Atai Holdco, Inc. Delaware Atai Life Sciences US, Inc. Delaware Atai Life Sciences AG Germany Atai Life Sciences UK Ltd England and Wales Atai Therapeutics, Inc. (f.k.a. Viridia Life Sciences, Inc.) Delaware DemeRx IB, Inc.* Delaware EmpathBio, Inc. Delaware EntheogeniX Biosciences, Inc.* Delaware GABA Therapeutics, Inc |
|
| March 28, 2024 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED ATAI Life Sciences N.V. (the “Company,” “we,” “us” and “our”) has the following class of securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common shares, par val |
|
| March 12, 2024 |
IGXT / IntelGenx Technologies Corp. / ATAI Life Sciences B.V. - SC 13D/A Activist Investment SC 13D/A 1 d757113dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* IntelGenx Technologies Corp. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 45822R101 (CUSIP Number) Ryan Barrett ATAI Life Sciences AG Wallstraße 16, 10179 Berlin, German |
|
| March 12, 2024 |
THIRD AMENDED AND RESTATED LOAN AGREEMENT EX-99.15 3 d757113dex9915.htm EX-99.15 Exhibit 99.15 THIRD AMENDED AND RESTATED LOAN AGREEMENT This THIRD AMENDED AND RESTATED LOAN AGREEMENT, dated as of March 8, 2024 (as amended, restated, modified and/or supplemented, from time to time, this “Agreement”), amending and restating the Amended and Restated Loan Agreement originally effective as of March 8, 2021 and as amended and restated as of Se |
|
| March 12, 2024 |
AMENDMENT TO SUBSCRIPTION AGREEMENT EX-99.14 2 d757113dex9914.htm EX-99.14 Exhibit 99.14 AMENDMENT TO SUBSCRIPTION AGREEMENT THIS AMENDMENT TO SUBSCRIPTION AGREEMENT (this “Amendment”) is made as of September 30, 2023 by and among IntelGenx Technologies Corp. (the “Issuer”) and atai Life Sciences AG (the “Subscriber”). RECITALS: WHEREAS the Issuer and the Subscriber entered into that certain subscription agreement dated August 31, 2 |
|
| February 13, 2024 |
ATAI / Atai Life Sciences N.V. / Apeiron Investment Group Ltd. - SC 13G/A Passive Investment SC 13G/A 1 d787948dsc13ga.htm SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* ATAI Life Sciences N.V. (Name of Issuer) Common Shares (Title of Class of |
|
| February 6, 2024 |
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer EX-99.1 3 ef20020799ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 atai Life Sciences Appoints Anne Johnson as Chief Financial Officer NEW YORK and BERLIN, February 6, 2024 - atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”) today announced that Anne Johnson, the Company’s interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial |
|
| February 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 1, 2024 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation |
|
| February 6, 2024 |
Separation Agreement between Mr. Stephen Bardin and atai Life Sciences N.V., dated February 6, 2024 Exhibit 10.1 Separation Agreement and Release This Separation Agreement and Release (“Agreement”) is made by and between Stephen Bardin (“Executive”), ATAI Life Sciences N.V. (“Parent”) and ATAI Life Sciences US, Inc., a Delaware corporation (together with any successor, the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). Capitalized terms used but |
|
| January 23, 2024 |
Exhibit 10.1 DATE: 18 January 2024 SHARE PURCHASE DEED Between THE SELLERS and THE BUYER CMS Cameron McKenna Nabarro Olswang LLP Cannon Place 78 Cannon Street London EC4N 6AF T +44 20 7367 3000 F +44 20 7367 2000 cms.law TABLE OF CONTENTS 1. Interpretation 1 2. Sale and purchase 3 3. Warranties 3 4. Purchase Price 5 5. Completion 6 6. Post-Completion 6 7. Confidentiality 7 8. Further assurance 7 9 |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 18, 2024 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation |
|
| January 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 7, 2024 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation o |
|
| January 9, 2024 |
Exhibit 10.1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Termination and New Consultancy Agreement between 1. ATAI Life Sciences AG, a German stock corporation (Aktiengesellschaft), with its business address at Wallstraße 16, 10179 Berlin, Germany, registered with th |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 3, 2024 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation o |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2024 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation o |
|
| January 4, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATIN ONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. DATE: JANUARY 3, 2024 AMENDED AND RESTATED SUBSCRIPTION AND SHAREHOLDERS’ AGREEMENT RELATING TO BECKLEY PSYTECH LIMITED Between THE NEW INVESTOR and THE |
|
| January 4, 2024 |
Exhibit 10.2 DATE: 202[ ● ] FORM OF SHARE PURCHASE DEED Between THE SELLERS and THE BUYER CMS Cameron McKenna Nabarro Olswang LLP Cannon Place 78 Cannon Street London EC4N 6AF T +[***] F +[***] cms.law TABLE OF CONTENTS 1. Interpretation 1 2. Sale and purchase 3 3. Warranties 3 4. Purchase Price 5 5. Completion 5 6. Post-Completion 6 7. Confidentiality 7 8. Further assurance 7 9. Assignment and ot |
|
| January 4, 2024 |
Exhibit 99.1 Healingmental health disorders so that everyone everywhere can live a more fulfilled life. Company Overview Company Overview – January 2024 All references in this presentation to “we”, “us”, “our”, “atai”, or the “Company” refer to ATAI Life Sciences N.V. and its consolidated subsidiaries, unless the context otherwise requires. This presentation contains forward-looking statements wit |
|
| January 4, 2024 |
Exhibit 99.1 atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics - Strategic investment in Beckley Psytech reinforces atai’s position as the biopharmaceutical company with the largest and most diverse portfolio of clinical-stage psychedelic candidates - Two patent-protected, clinical-stage programs BPL-003 (intr |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2023 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40493 ATAI Life Sciences N. |
|
| November 14, 2023 |
Exhibit 10.2 [***] Certain information in this document has been omitted from this exhibit because (i) the Company customarily and actually treats such information as private or confidential and (ii) the omitted information is not material.] EXECUTION COPY FOURTH AMENDMENT TO SERIES A PREFERRED STOCK PURCHASE AGREEMENT THIS FOURTH AMENDMENT TO SERIES A PREFERRED STOCK PURCHASE AGREEMENT (this “Ame |
|
| November 14, 2023 |
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights Exhibit 99.1 atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights - Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this year. - Phase 1 data of VLS-01 (a proprietary oral transmucosal film formulation of DMT) demonstrated that |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 10, 2023 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 29, 2023 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporatio |
|
| September 7, 2023 |
IGXT / IntelGenx Technologies Corp / ATAI Life Sciences B.V. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* IntelGenx Technologies Corp. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 45822R101 (CUSIP Number) Ryan Barrett ATAI Life Sciences AG Wallstraße 16, 10179 Berlin, Germany +49 (0) 89 2153 9035 (Name, |
|
| September 7, 2023 |
EX-99.9 Certain information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the reporting person treats as private or confidential. Exhibit 99.9 AGREEMENT This letter agreement (this “Agreement”) is dated August 31, 2023 among ATAI Life Sciences AG (“ATAI”), IntelGenx Technologies Corp. (the “Company”) and IntelGenx Corp. |
|
| September 7, 2023 |
INTELGENX TECHNOLOGIES CORP. (A Delaware Corporation) SUBSCRIPTION DOCUMENTS EX-99.8 Exhibit 99.8 INTELGENX TECHNOLOGIES CORP. (A Delaware Corporation) SUBSCRIPTION DOCUMENTS SUBSCRIPTION AGREEMENT INTELGENX TECHNOLOGIES CORP. Gentlemen (Ladies): The undersigned (the “Subscriber”) hereby tenders this subscription and applies for the purchase of 2,220 units (the “Initial Units”) of IntelGenx Technologies Corp., a Delaware corporation (the “Issuer”), with each Initial Unit c |
|
| August 31, 2023 |
Exhibit 10.1 AMENDED EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of this 25th of August 2023, by and between ATAI Life Sciences US, Inc. a Delaware corporation (the “Company”) and Stephen Bardin (the “Executive”). The Company and the Executive may each be referred to in this Agreement individually, as a “Party” and collectively, |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2023 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not applicable (State or other jurisdiction of incorporation o |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2023 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation o |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q n (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40493 ATAI Life Sciences N. |
|
| August 10, 2023 |
Exhibit 99.1 atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine) - Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients with Cognitive Impairment Associated with Schizophrenia - DMX-1002 (Ibogaine) Phase 1 results enable d |
|
| May 31, 2023 |
Exhibit 10.1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT This SECOND Amendment to Loan and Security Agreement (this “Amendment”) is dated as of May 26, 2023 and is entered into by and among ATAI LIFE SCIENCES N.V., a pu |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 26, 2023 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or o |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 16, 2023 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or o |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 11, 2023 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or o |
|
| May 11, 2023 |
Exhibit 99.1 atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates - RL-007: First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia. - GRX-917: Presented PD data from the completed Phase 1 study, which suggest the potential for anxiolytic effects without the significant sedative effects seen |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q n (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40493 ATAI Life Sciences N. |
|
| April 28, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 14, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 24, 2023 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED ATAI Life Sciences N.V. (the “Company,” “we,” “us” and “our”) has the following class of securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common shares, par val |
|
| March 24, 2023 |
Exhibit 10.30 [***] Certain information in this document has been omitted from this exhibit because (i) the Company customarily and actually treats such information as private or confidential and (ii) the omitted information is not material. OMNIBUS AMENDMENT THIS OMNIBUS AMENDMENT (this “Amendment”) is entered into as of October 05, 2022, by and among ATAI LIFE SCIENCES AG, a German corporation ( |
|
| March 24, 2023 |
Exhibit 10.29 [***] Certain information in this document has been omitted from this exhibit because (i) the Company customarily and actually treats such information as private or confidential and (ii) the omitted information is not material. SECOND AMENDMENT TO SERIES A PREFERRED STOCK PURCHASE AGREEMENT THIS SECOND AMENDMENT TO SERIES A PREFERRED STOCK PURCHASE AGREEMENT (this “Second Amendment”) |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2023 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or |
|
| March 24, 2023 |
Exhibit 99.1 INDEX TO THE FINANCIAL STATEMENTS Consolidated Financial Statements of COMPASS Pathways Plc INDEX TO ANNUAL CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID 876) F-2 Consolidated Balance Sheets F-5 Consolidated Statements of Operations and Comprehensive Loss F-6 Consolidated Statements of Convertible Preferred Shares and Sharehol |
|
| March 24, 2023 |
EX-21 7 atai-ex211.htm EX-21.1 Exhibit 21.1 Subsidiaries of the Registrant Name State or Other Jurisdiction of Incorporation or Organization DemeRx IB, Inc. Delaware DemeRx NB, Inc. Delaware GABA Therapeutics, Inc. Delaware Invyxis, Inc. Delaware TryptageniX, Inc. Delaware Kures Inc. Delaware Recognify Life Sciences, Inc. Delaware Perception Neuroscience Holdings, Inc. Delaware Viridia Life Scienc |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . |
|
| March 24, 2023 |
EX-99.1 Exhibit 99.1 atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights • atai’s development candidates, such as RL-007 and GRX-917, all represent significant opportunities to address unmet medical needs of patients living with mental health conditions • Continued operational progress on robust clinical pipeline, with multiple p |
|
| March 24, 2023 |
Execution Version Exhibit 10.27 First AMENDMENT TO LOAN AND SECURITY AGREEMENT This First Amendment to Loan and Security Agreement (this “Amendment”) is dated as of March 13, 2023 and is entered into by and among ATAI LIFE SCIENCES N.V., a public limited liability company (naamloze vennootschap) incorporated under the laws of the Netherlands, having its corporate seat (statutaire zetel) in Amsterd |
|
| March 24, 2023 |
Exhibit 10.28 [***] Certain information in this document has been omitted from this exhibit because (i) the Company customarily and actually treats such information as private or confidential and (ii) the omitted information is not material. AMENDMENT TO SERIES A PREFERRED STOCK PURCHASE AGREEMENT THIS AMENDMENT TO SERIES A PREFERRED STOCK PURCHASE AGREEMENT (this “Amendment”) is entered into as o |
|
| February 10, 2023 |
ATAI / ATAI Life Sciences N.V. / Apeiron Investment Group Ltd. - SC 13G/A Passive Investment SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* ATAI Life Sciences N.V. (Name of Issuer) Common Shares (Title of Class of Securities) N0731H103 (CUSIP N |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2022 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation |
|
| November 10, 2022 |
Exhibit 10.2 Page 1 of 30 ARBEITSVERTRAG EMPLOYMENT AGREEMENT (im folgenden ?Arbeitsvertrag? genannt) (hereinafter referred to as ?Employment Agreement?) zwischen der between atai Life Sciences AG Wallstra?e 16 10179 Berlin, Germany (im folgenden ?Arbeitgeber? genannt) (hereinafter referred to as ?Employer?) und and Stephen Rodrick Bardin Yorckstra?e 69 10965 Berlin, Germany (im folgenden ?Arbeitn |
|
| November 10, 2022 |
EX-1.1 Exhibit 1.1 Certain identified information, indicated by [***], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. OPEN MARKET SALE AGREEMENTSM November 10, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: ATAI Life Sciences N.V., a Dutch public company with limited li |
|
| November 10, 2022 |
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update EX-99.1 Exhibit 99.1 PRESS RELEASE atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update - Last patient dosed in the Phase 2a proof-of-concept trial of PCN-101 (R-ketamine) for treatment-resistant depression (TRD), with topline results expected around year-end 2022. - Announced positive preliminary pharmacokinetics and pharmacodynamics results in a Phase 1 study of GR |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 10, 2022 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q n (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40493 ATAI Life Sciences N. |
|
| November 10, 2022 |
Up to $150,000,000 Common Shares 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-265970 PROSPECTUS SUPPLEMENT (to Prospectus dated July 11, 2022) Up to $150,000,000 Common Shares We have entered into an Open Market Sale AgreementSM, or sales agreement, with Jefferies LLC, or Jefferies, relating to the sale of our common shares, nominal value €0.10 per share, offered by this prospectus supplement and |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 2, 2022 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation |
|
| October 14, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 13, 2022 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation |
|
| September 19, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT ? SCHEDULE 14A INFORMATION ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| September 9, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT ? SCHEDULE 14A INFORMATION ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| August 15, 2022 |
atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital Exhibit 99.1 atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital - Non-dilutive financing facility, plus $312M existing cash on hand as of June 30, 2022, gives atai access to up to $487M to continue developing next generation mental health treatments - Flexible draw availability provides optionality to optimize liquidity and capital structure moving forward N |
|
| August 15, 2022 |
Exhibit 10.1 [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT is made and dated as of August 9, 2022 and is entered into by and among ATAI LIFE SCIENCES N.V., a public limited liability company (naamloze vennoot |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 15, 2022 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation o |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40493 ATAI Life Sciences N. |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 9, 2022 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or |
|
| August 15, 2022 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into as of this 11 of June 2022, by and between ATAI Life Sciences US, Inc. a Delaware corporation (the ?Company?) and Stephen Bardin (the ?Executive?). The Company and the Executive may each be referred to in this Agreement individually, as a ?Party? and collectively, as the ?Par |
|
| August 15, 2022 |
atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update Exhibit 99.1 PRESS RELEASE atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update - Added an anticipated additional year of runway into 2025 through securing non-dilutive debt facility from Hercules combined with execution of cost optimizations by prioritizing atai?s development programs with anticipated meaningful near-term clinical value inflections - Key achieved R&D |
|
| August 1, 2022 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 28, 2022 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or |
|
| July 7, 2022 |
ATAI Life Sciences N.V. c/o Mindspace Krausenstraße 9-10 10117 Berlin, Germany ATAI Life Sciences N.V. c/o Mindspace Krausenstra?e 9-10 10117 Berlin, Germany July 7, 2022 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Ada D. Sarmento Re: ATAI Life Sciences N.V. Registration Statement on Form S-3 Filed July 1, 2022 Registration No. 333-265970 Ladies and Gentlemen: |
|
| July 1, 2022 |
Exhibit 4.2 ATAI LIFE SCIENCES N.V. INDENTURE Dated as of [ ], 20[ ] [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II. THE SECURITIES 6 Section 2.1 Issuable in Series 6 Section 2.2 Establis |
|
| July 1, 2022 |
Articles of Association of ATAI Life Sciences N.V. (translated into English), currently in effect Exhibit 3.1 AKTE VAN PARTI?LE STATUTENWIJZIGING ATAI LIFE SCIENCES N.V. Op ??n juli tweeduizend twee?ntwintig is voor mij, mr. Jan-Mathijs Petrus Hermans, notaris te Amsterdam, verschenen: de heer mr. Abraham Anno Christoffel Bloemers, werkzaam op mijn kantoor aan het Gustav Mahlerplein 2 te Amsterdam, geboren te Rheden op negen september negentienhonderd zesenzeventig. De verschenen persoon, hand |
|
| July 1, 2022 |
As filed with the Securities and Exchange Commission on July 1, 2022 Table of Contents As filed with the Securities and Exchange Commission on July 1, 2022 Registration No. |
|
| July 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) ATAI Life Sciences N. |
|
| June 17, 2022 |
Exhibit 10.1 Transition and Separation Agreement This Transition and Separation Agreement (?Agreement?) is made as of June 15, 2022 (the ?Notice Date?), by and among ATAI Life Sciences US, Inc. (the ?Company?), ATAI Life Sciences N.V. (?Parent?) and Greg Weaver (the ?Executive?) (collectively referred to as the ?parties? or individually referred to as a ?party?). Capitalized terms used but not def |
|
| June 17, 2022 |
Stephen Bardin to Join atai Life Sciences as CFO Designate Exhibit 99.1 Stephen Bardin to Join atai Life Sciences as CFO Designate ? Stephen Bardin will join as CFO Designate on June 27, 2022 ? After a transition period, atai?s current CFO Greg Weaver will be moving into a part time strategic advisory role NEW YORK and BERLIN, JUNE 17, 2022 @ 7:59 AM EST [NEWSWIRE] // atai Life Sciences N.V., (Nasdaq: ATAI) (?atai? or the ?Company?), a clinical stage biop |
|
| June 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 15, 2022 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or |
|
| May 27, 2022 |
Exhibit 3.2 In this translation an attempt has been made to be as literal as possible without jeopardizing the overall continuity. Inevitably, differences may occur in translation, and if so, by law the Dutch text will govern. Complete continuous text of the articles of association ATAI Life Sciences N.V. @ 2022 ARTICLES OF ASSOCIATION 1 DEFINITIONS (FOR CONVENIENCE SAKE THE FOLLOWING DEFINITIONS |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 25, 2022 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or o |
|
| May 27, 2022 |
Articles of Association of ATAI Life Sciences N.V., as amended on May 25, 2022. 1 Exhibit 3.1 In this translation an attempt has been made to be as literal as possible without jeopardizing the overall continuity. Inevitably, differences may occur in translation, and if so, by law the Dutch text will govern. Complete continuous text of the articles of association ATAI Life Sciences N.V. @ 2022 ARTICLES OF ASSOCIATION 1 DEFINITIONS (FOR CONVENIENCE SAKE THE FOLLOWING DEFINITION |
|
| May 16, 2022 |
Exhibit 99.1 atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update ? Strong execution across atai?s three strategic pillars: rapid acting pharmacological intervention, ongoing digital support and biomarker-driven precision mental health ? Key milestones include first subject dosed in Phase 1 KUR-101, launch of drug discovery engine Invyxis, initiation of Psyber usabil |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40493 ATAI Life Sciences N. |
|
| May 16, 2022 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED ATAI Life Sciences N.V. (the ?Company,? ?we,? ?us? and ?our?) has the following class of securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common shares, par val |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 16, 2022 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or o |
|
| April 29, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT ? SCHEDULE 14A INFORMATION ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 18, 2022 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT ? SCHEDULE 14A INFORMATION ? Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 30, 2022 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED ATAI Life Sciences N.V. (the ?Company,? ?we,? ?us? and ?our?) has the following class of securities registered pursuant to Section 12(b) of the Exchange Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common shares, par val |
|
| March 30, 2022 |
Exhibit 99.1 atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform ? Highlights included positive Phase 2b data with COMP360 from a ground-breaking treatment resistant depression (TRD) trial, highly encouraging Phase 2a proof-of-mechanism data with RL-007 in cognitive i |
|
| March 30, 2022 |
Exhibit 99.1 COMPASS Management Evaluation of Controls & Procedures Evaluation of Disclosure Controls and Procedures Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . |
|
| March 30, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 ATAI Life Sciences N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not applicable (State or other jurisdiction of incorporation) ( |
|
| March 30, 2022 |
Exhibit 21.1 Subsidiaries of the Registrant Name State or Other Jurisdiction of Incorporation or Organization DemeRx IB, Inc. Delaware DemeRx NB, Inc. Delaware GABA Therapeutics, Inc. Delaware Invyxis, Inc. Delaware TryptageniX, Inc. Delaware Kures Inc. Delaware Recognify Life Sciences, Inc. Delaware Neuronasal, Inc. Delaware Perception Neuroscience Holdings, Inc. Delaware Viridia Life Sciences, I |
|
| March 1, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including amendments thereto) with respect to the Common Shares of ATAI Life Sciences N.V. beneficially owned by each of them, and further agree that this Joint Filing |
|
| March 1, 2022 |
ATAI / ATAI Life Sciences N.V. / Galaxy Group Funding ECI U LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ATAI Life Sciences N.V. (Name of Issuer) Common Shares (Title of Class of Securities) N0731H103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 10, 2022 |
ATAI / ATAI Life Sciences N.V. / Apeiron Investment Group Ltd. - SC 13G Passive Investment Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* ATAI Life Sciences N.V. (Name of Issuer) Common shares (Title of Class of Securities) N0731H103 (CUSIP Number) Dec |
|
| February 10, 2022 |
Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. |
|
| December 15, 2021 |
Exhibit 99.1 Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share Lock-up Agreements ? Apeiron and other key shareholders enter into voluntary lock-up agreements ? This voluntary lock-up extends trading restrictions by 24 months for Apeiron and 12 months for other investors ? Demonstrates strong ongoing confidence in atai?s diversifi |
|
| December 15, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 15, 2021 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation |
|
| December 1, 2021 |
GB:CMPS / Compass Pathways Plc / ATAI Life Sciences B.V. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* COMPASS Pathways plc (Name of Issuer) Ordinary Shares** (Title of Class of Securities) 20451W101** (CUSIP Number) Ryan Barrett ATAI Life Sciences AG Krausenstra?e 9-10, 10117 Berlin, Germany +49 (0) 89 2153 9035 (Name, Address and Telephone Number of Per |
|
| November 29, 2021 |
GB:CMPS / Compass Pathways Plc / ATAI Life Sciences B.V. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* COMPASS Pathways plc (Name of Issuer) Ordinary Shares** (Title of Class of Securities) 20451W101** (CUSIP Number) Ryan Barrett ATAI Life Sciences AG Krausenstraße 9-10, 10117 Berlin, Germany +49 (0) 89 2153 9035 (Name, Address and Telephone Numb |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q M UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40493 ATAI Life Sciences N. |
|
| November 15, 2021 |
Exhibit 99.1 atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update -Positive topline results from COMP360?s Phase 2b study- -RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4- -Continued progress across 11 therapeutic programs, including initiation of Perception?s Phase 2a and DemeRx?s Phase 1/2 trials as well as in |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2021 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation |
|
| August 20, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q/A (Amendment No. |
|
| August 16, 2021 |
Articles of Association of ATAI Life Sciences N.V. (translated into English), currently in effect Exhibit 3.1 1 AKTE VAN OMZETTING EN WIJZIGING STATUTEN Op achttien juni tweeduizend eenentwintig is voor mij, mr. Jan-Mathijs Petrus Hermans, notaris te Amsterdam, verschenen: mevrouw mr. Sophie Theodora Cornelia Prosman, werkzaam op mijn kantoor aan het Gustav Mahlerplein 2 te Amsterdam, geboren te Maasdriel op veertien oktober negentienhonderd drie?nnegentig. De verschenen persoon, handelend als |
|
| August 16, 2021 |
Exhibit 99.1 atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update -Successfully completed Initial Public Offering on Nasdaq raising $258.8 million in gross proceeds, including the underwriters? over-allotment- -Received $20 million upfront payment from Otsuka as part of the first major collaboration between a biopharmaceutical company developing psychedelics and lar |
|
| August 16, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 16, 2021 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation o |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40493 ATAI Life Sciences N. |
|
| August 11, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 11, 2021 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation o |
|
| August 11, 2021 |
Healingmental health disorders so that everyone everywhere can live a more fulfilled life. |
|
| July 13, 2021 |
Exhibit 99.1 Company Overview Company Overview Exhibit 99.1 Company Overview Company Overview 02 Disclaimer This presentation may include forward-looking statements. All statements other statements. We caution you therefore against relying on these forward-looking necessarily subject to uncertainty and risk due to a variety of factors, including than statements of historical facts contained in thi |
|
| July 13, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 13, 2021 ATAI LIFE SCIENCES N.V. (Exact name of registrant as specified in its charter) The Netherlands 001-40493 Not Applicable (State or other jurisdiction of incorporation or |
|
| June 28, 2021 |
Registration No. 333- As filed with the United States Securities and Exchange Commission on June 28, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ATAI Life Sciences N.V. (Exact name of Registrant as specified in its charter) The Netherlands Not Applicable (State or other jurisdiction of incorporation o |
|
| June 21, 2021 |
Table of Contents Filed pursuant to Rule 424(b)(4) Registration Nos. 333-255383 and 333-257184 15,000,000 Shares ATAI Life Sciences B.V. to be converted and renamed ATAI Life Sciences N.V. Common Shares This is the initial public offering of common shares of ATAI Life Sciences B.V. Prior to this offering, there has been no public market for our common shares. The initial public offering price is $ |
|
| June 17, 2021 |
As filed with the U.S. Securities and Exchange Commission on June 17, 2021. As filed with the U.S. Securities and Exchange Commission on June 17, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ATAI Life Sciences B.V.* (Exact Name of Registrant as Specified in its Charter) The Netherlands 2834 Not Applicable (State or Other Jurisdiction of Incorporation or |
|
| June 15, 2021 |
Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, NY 10010 Citigroup Global Markets Inc. |
|
| June 15, 2021 |
As filed with the Securities and Exchange Commission on June 15, 2021. Table of Contents As filed with the Securities and Exchange Commission on June 15, 2021. |
|
| June 15, 2021 |
ATAI Life Sciences B.V. c/o Mindspace Krausenstraße 9-10 10117 Berlin, Germany ATAI Life Sciences B.V. c/o Mindspace Krausenstra?e 9-10 10117 Berlin, Germany June 15, 2021 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Gary Newberry Kevin Vaughn Jason Drory Suzanne Hayes Re: ATAI Life Sciences B.V. Registration Statement on Form S-1 (File No. 333-255383) Ladies an |
|
| June 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 ATAI Life Sciences B.V.* (Exact name of registrant as specified in its charter) The Netherlands Not Applicable (State of incorporation or organization) (I.R.S. Employer Identification No.) ATAI L |
|
| June 11, 2021 |
As filed with the Securities and Exchange Commission on June 11, 2021. Table of Contents As filed with the Securities and Exchange Commission on June 11, 2021. |
|
| June 11, 2021 |
Form of Underwriting Agreement Exhibit 1.1 [?] Common Shares ATAI LIFE SCIENCES B.V. UNDERWRITING AGREEMENT June [?], 2021 CREDIT SUISSE SECURITIES (USA) LLC CITIGROUP GLOBAL MARKETS INC. COWEN AND COMPANY, LLC BERENBERG CAPITAL MARKETS LLC, As Representatives of the several Underwriters, c/o Credit Suisse Securities (USA) LLC Eleven Madison Avenue New York, N.Y. 10010-3629 c/o Citigroup Global Markets Inc. 388 Greenwich Street |
|
| June 11, 2021 |
Exhibit 3.1 1 In this translation an attempt has been made to be as literal as possible without jeopardizing the overall continuity. Inevitably, differences may occur in translation, and if so, by law the Dutch text will govern. DEED OF CONVERSION AND AMENDMENT OF ARTICLES OF ASSOCIATION On this [ ] day of June two thousand twenty-one appeared before me, Jan-Mathijs Petrus Hermans, civil-law notar |
|
| June 11, 2021 |
Remuneration Policy for the Board of Supervisory Directors of ATAI Life Sciences N.V. Exhibit 10.23 REMUNERATION POLICY FOR THE BOARD OF SUPERVISORY DIRECTORS OF ATAI LIFE SCIENCES N.V. Approved by the general meeting of shareholders and in effect as per the Effective Date 1. PRINCIPLES The following sets forth the remuneration for the Board of Supervisory Directors (the ?Board of Supervisory Directors? and individually referred to as a ?Supervisory Director?) of ATAI Life Sciences |
|
| June 11, 2021 |
Partnership Agreement of ATAI Life Sciences HSOP GbR, dated August 21, 2020 Exhibit 10.22 Partnership Agreement (Gesellschaftsvertrag) of ATAI Life Sciences HSOP GbR Dated: 21 August 2020 Execution version PARTNERS (GESELLSCHAFTER) (1) Florian Brand, born 4 September 1986, address: Yorckstr. 69, 10965 Berlin (including his legal successors, if any, hereinafter “Partner Without Asset Share”); (2) ATAI Life Sciences AG, a German stock corporation registered with the commerc |
|
| June 11, 2021 |
Form of Option Award Agreement under 2021 Incentive Award Plan Exhibit 10.17 ATAI LIFE SCIENCES N.V. 2021 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Capitalized terms not specifically defined in this Stock Option Grant Notice (the “Grant Notice”) have the meanings given to them in the 2021 Incentive Award Plan (as amended from time to time, the “Plan”) of ATAI Life Sciences N.V. (the “Company”). The Company has granted to the participant listed below (“Pa |
|
| June 11, 2021 |
Rules of the Supervisory Board of ATAI Life Sciences N.V. EX-3.3 5 d39052dex33.htm EX-3.3 Exhibit 3.3 RULES OF THE BOARD OF SUPERVISORY DIRECTORS ATAI LIFE SCIENCES N.V. 1 INTRODUCTION 1.1 These rules govern the organisation, decision-making and other internal matters of the Board of Supervisory Directors. In performing their duties, the Supervisory Directors shall comply with these rules. 1.2 These rules shall be posted on the Company’s website. 2 DEFIN |
|
| June 11, 2021 |
Rules of the Management Board of ATAI Life Sciences N.V. Exhibit 3.2 RULES OF THE BOARD OF MANAGING DIRECTORS ATAI LIFE SCIENCES N.V. 1 INTRODUCTION 1.1 These rules govern the organisation, decision-making and other internal matters of the Board of Managing Directors. In performing their duties, the Managing Directors shall comply with these rules. 1.2 These rules shall be posted on the Company’s website. 2 DEFINITIONS AND INTERPRETATION 2.1 In these ru |
|
| June 11, 2021 |
EX-10.25 23 d39052dex1025.htm EX-10.25 Exhibit 10.25 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), is made and entered into as of this of June 2021, by and between ATAI Life Sciences US, Inc. a Delaware corporation (the “Company”) and Rolando Gutiérrez Esteinou (the “Executive”). The Company and the Executive may each be referred to in |
|
| June 11, 2021 |
Exhibit 3.4 1 DEED OF ISSUE ATAI LIFE SCIENCES N.V. THE UNDERSIGNED: ATAI Life Sciences N.V., a public company (?naamloze vennootschap?), having its corporate seat in Amsterdam, offices at c/o Mindspace Krausenstra?e 9-10, 10117 Berlin, Federal Republic of Germany, and registered with the Trade Register of the Chamber of Commerce under number 80299776 (the Company). NOW HEREBY AGREES AS FOLLOWS: 1 |
|
| June 11, 2021 |
EX-10.4 13 d39052dex104.htm EX-10.4 Exhibit 10.4 The articles of association of ATAI Life Sciences N.V. will provide in clause 23 for the following indemnification for the following persons: Indemnified Officer (Gevrijwaarde Fuctionaris) means: a current or former Managing Director or Supervisory Director and such other current of former officer or employee of the Company or a Group Company, as de |
|
| June 11, 2021 |
Exhibit 10.1 SERVICE AGREEMENT THE UNDERSIGNED: 1. ATAI LIFE SCIENCES N.V., having its registered office in Amsterdam, the Netherlands, (referred to below as the “Company”); and 2. Florian Brand, residing at the most recent address for the Managing Director in the Company’s personnel files (referred to below as “Managing Director”); WHEREAS: (a) The Company is converted into a public company under |
|
| June 11, 2021 |
Remuneration policy for the Board of Managing Directors of ATAI Life Sciences N.V. EX-10.24 22 d39052dex1024.htm EX-10.24 Exhibit 10.24 REMUNERATION POLICY FOR THE BOARD OF MANAGING DIRECTORS OF ATAI LIFE SCIENCES N.V. Approved by the general meeting of shareholders and in effect as per the Effective Date 1 GENERAL 1.1 Principles The following sets forth the remuneration for the Board of Managing Directors (the “Board of Managing Directors”, and individually referred to as a ‘Ma |
|
| June 11, 2021 |
Form of Stock Option Agreement under 2020 Employee, Director and Consultant Equity Incentive Plan Exhibit 10.21 Option No. ATAI LIFE SCIENCES AG Stock Option Grant Notice Stock Option Grant under the Company?s 2020 Employee, Director and Consultant Equity Incentive Plan 1. Name and Address of Participant: 2. Date of Option Grant: 3. Type of Grant (ISO or Non-Qualified) 1: 4. Maximum Number of Shares for which this Option is exercisable: 5. Exercise (purchase) price per Share: 6. Option Expirat |
|
| June 11, 2021 |
2020 Employee, Director, and Consultant Equity Incentive Plan EX-10.20 18 d39052dex1020.htm EX-10.20 Exhibit 10.20 ATAI LIFE SCIENCES AG 2020 EMPLOYEE, DIRECTOR AND CONSULTANT EQUITY INCENTIVE PLAN 1. DEFINITIONS. Unless otherwise specified or unless the context otherwise requires, the following terms, as used in this ATAI Life Sciences AG 2020 Employee, Director and Consultant Equity Incentive Plan, have the following meanings: Administrator means the Manag |
|
| June 11, 2021 |
Form of Restricted Stock Unit Agreement under 2021 Incentive Award Plan Exhibit 10.19 ATAI LIFE SCIENCES N.V. 2021 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2021 Incentive Award Plan (as amended from time to time, the “Plan”) of ATAI Life Sciences N.V. (the “Company”). The Company has granted to the participant |
|
| June 11, 2021 |
Atai Life Sciences N.V. 2021 Incentive Award Plan Exhibit 10.5 ATAI LIFE SCIENCES N.V. 2021 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan?s purpose is to enhance the Company?s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE II. ELIGIBI |
|
| June 11, 2021 |
Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Agreement?), is made and entered into as of this of June 2021, by and between ATAI Life Sciences US, Inc. a Delaware corporation (the ?Company?) and Srinivas Rao (the ?Executive?). The Company and the Executive may each be referred to in this Agreement individually, as a ?Party? and collect |
